Grewal Nimrat, Gittenberger-de Groot Adriana C, DeRuiter Marco C, Klautz Robert J M, Poelmann Robert E, Duim Sjoerd, Lindeman Johannes H N, Koenraadt Wilke M C, Jongbloed Monique R M, Mohamed Salah A, Sievers Hans-Hinrich, Bogers Ad J J C, Goumans Marie-José
Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, Netherlands Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, Netherlands.
Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands.
Eur J Cardiothorac Surg. 2014 Nov;46(5):831-9. doi: 10.1093/ejcts/ezu319. Epub 2014 Aug 26.
The clinical course of many patients with a bicuspid aortic valve (BAV) is complicated by ascending aortic dilatation. Currently, the indication for aortic surgery is solely based on the aortic diameter and subsequently only a small proportion of BAV patients undergoing valve surgery require concomitant ascending aortic replacement based on these recommendations. Unfortunately, a substantial number of BAV patients still develop aortic dilatation in the future and would potentially benefit from a more aggressive approach towards ascending aortic replacement. We, therefore, designed this study to identify molecular biological markers in the aortic wall predictive of aortopathy in BAV.
Ascending aortic wall specimen of BAV (n = 36) and tricuspid aortic valve (TAV) (n = 23), both without and with (>44 mm) dilatation were investigated histologically and immunohistochemically for the expression of markers for vascular remodelling [transforming growth factor (TGF)-β, phosphorylated Smad2, matrix metalloproteinase 9 (MMP9)], cellular differentiation [c-Kit, phosphorylated-c-Kit, hypoxia-inducable factor-1 alpha (HIF1α)] and haemodynamic influences on the aortic wall [endothelial nitric oxide (eNOS)].
All BAV patients showed significantly less inflammation (P < 0.001) and an altered intima/media ratio when compared with TAV patients. The expression of markers of a signalling pathway characteristic for cellular dedifferentiation, as exemplified by the marked expression of c-Kit, phosphorylated c-Kit and HIF1α; in the dilated BAV group was however completely comparable with only a subgroup of the non-dilated BAV (BAb), whereas the remainder of the non-dilated BAV group (BAa) was significantly distinct. This difference between the dilated BAV and BAa was further confirmed in the expression of TGF-β, phosphorylated Smad2, MMP9 and eNOS. Besides the expression pattern, similarity in the dilated BAV and BAb was also noted clinically in the most common variant of commissure position and conjoined raphe of the BAV. Based on these observations, we consider the BAb group a likely candidate for future dilatation as opposed to the BAa group.
Using a panel of molecular tissue markers, the non-dilated BAV patients can be divided into groups susceptible and non-susceptible to aortopathy.
许多二叶式主动脉瓣(BAV)患者的临床病程因升主动脉扩张而复杂化。目前,主动脉手术的指征仅基于主动脉直径,因此根据这些建议,接受瓣膜手术的BAV患者中只有一小部分需要同期进行升主动脉置换。不幸的是,大量BAV患者未来仍会发生主动脉扩张,可能会从更积极的升主动脉置换方法中获益。因此,我们设计了这项研究,以确定BAV患者主动脉壁中预测主动脉病变的分子生物学标志物。
对BAV组(n = 36)和三叶式主动脉瓣(TAV)组(n = 23)的升主动脉壁标本进行组织学和免疫组织化学研究,标本包括无扩张和有扩张(>44 mm)的情况,检测血管重塑标志物[转化生长因子(TGF)-β、磷酸化Smad2、基质金属蛋白酶9(MMP9)]、细胞分化标志物[c-Kit、磷酸化-c-Kit、缺氧诱导因子-1α(HIF1α)]以及血流动力学对主动脉壁的影响标志物[内皮型一氧化氮(eNOS)]的表达。
与TAV患者相比,所有BAV患者均表现出明显较轻的炎症(P < 0.001)和内膜/中膜比值改变。以c-Kit、磷酸化c-Kit和HIF1α的显著表达为例,细胞去分化特征性信号通路标志物在扩张型BAV组中的表达与仅非扩张型BAV的一个亚组(BAb)完全可比,而非扩张型BAV组的其余部分(BAa)则明显不同。TGF-β、磷酸化Smad2、MMP9和eNOS的表达进一步证实了扩张型BAV与BAa之间的这种差异。除了表达模式外,扩张型BAV和BAb在BAV最常见的瓣叶连合位置和联合嵴变体的临床表现上也有相似之处。基于这些观察结果,我们认为BAb组与BAa组相比,更有可能是未来发生扩张的候选对象。
使用一组分子组织标志物,可以将非扩张型BAV患者分为易患和不易患主动脉病变的组。